Biogen at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Biogen takes part in 2 sessions at BIO-Europe 2026 in Cologne. Its sessions cover AI in clinical trials and how to navigate a shifting regulatory landscape. The regulatory session, shared with Roche, looks at using the Biotech Act for innovation and global success.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Biogen Cambridge, Massachusetts | |
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. | Panel Tue Nov 10 16:00–16:45 AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed. Panel Tue Nov 10 15:00–15:45 Mastering the Shifting Regulatory Landscape: Leveraging the Biotech Act for Innovation and Global Success How the EU Biotech Act shapes cell and gene therapies, and how Europe compares with UK and US programmes for rare and personalised treatments. |
Instantly find 20 buyers from Biogen
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction